	US 11,884,725 B2
	Antibody against TIM-3 and application thereof
Qiang Li, Shanghai (CN); Tongtong Xue, Chengdu (CN); Yuncheng Zheng, Shanghai (CN); Liang Xiao, Chengdu (CN); Dengnian Liu, Chengdu (CN); Jianyu Sun, Shanghai (CN); Jiangjiang Hu, Chengdu (CN); Xinlu Ma, Shanghai (CN); Kangyong Zhu, Shanghai (CN); and Yuanli Li, Shanghai (CN)
Assigned to Ampsource Biopharma Shanghai Inc., Shanghai (CN)
Appl. No. 17/050,161
Filed by AMPSOURCE BIOPHARMA SHANGHAI INC., Shanghai (CN)
PCT Filed Apr. 22, 2019, PCT No. PCT/CN2019/083727 § 371(c)(1), (2) Date Oct. 23, 2020, PCT Pub. No. WO2019/206095, PCT Pub. Date Oct. 31, 2019.
Claims priority of application No. 201810371407.3 (CN), filed on Apr. 24, 2018.
Prior Publication US 2021/0238282 A1, Aug. 5, 2021
Int. Cl. C07K 16/28 (2006.01); A61P 35/00 (2006.01); A61K 45/06 (2006.01); A61K 39/00 (2006.01); C12N 5/12 (2006.01)

CPC C07K 16/2803 (2013.01) [A61K 45/06 (2013.01); A61P 35/00 (2018.01); C12N 5/12 (2013.01); A61K 2039/507 (2013.01)]

20 Claims

1. An antibody or an antigen-binding fragment thereof capable of specifically binding to TIM-3, comprising complementarity determining regions (CDRs) selected from following groups:

(a) following three CDRs of a heavy chain variable region (VH):

(i) CDR-H1, which has a sequence of CDR-H1 contained in a VH as shown by SEQ ID NO: 1, or has a sequence with one or more substitutions, deletions or additions relative to the sequence of CDR-H1 contained in the VH;

(ii) CDR-H2, which has a sequence of CDR-H2 contained in the VH as shown by SEQ ID NO: 1, or has a sequence with one or more substitutions, deletions or additions relative to the sequence of CDR-H2 contained in the VH; and

(iii) CDR-H3, which has a sequence of CDR-H3 contained in the VH as shown by SEQ ID NO: 1, or has a sequence with one or more substitutions, deletions or additions relative to the sequence of CDR-H3 contained in the VH; and/or

following three CDRs of a light chain variable region (VL):

(iv) CDR-L1, which has a sequence of CDR-L1 contained in a VL as shown by SEQ ID NO: 2, or has a sequence with one or more substitutions, deletions or additions relative to the sequence of CDR-L1 contained in the VL;

(v) CDR-L2, which has a sequence of CDR-L2 contained in the VL as shown by SEQ ID NO: 2, or has a sequence with one or more substitutions, deletions or additions relative to the sequence of CDR-L2 contained in the VL; and

(vi) CDR-L3, which has a sequence of CDR-L3 contained in the VL as shown by SEQ ID NO: 2, or has a sequence with one or more substitutions, deletions or additions relative to the sequence of CDR-L3 contained in the VL; or

(b) following three CDRs of a heavy chain variable region (VH):

(i) CDR-H1, which has a sequence of CDR-H1 contained in a VH as shown by SEQ ID NO: 7, or has a sequence with one or more substitutions, deletions or additions relative to the sequence of CDR-H1 contained in the VH;

(ii) CDR-H2, which has a sequence of CDR-H2 contained in the VH as shown by SEQ ID NO: 7, or has a sequence with one or more substitutions, deletions or additions relative to the sequence of CDR-H2 contained in the VH; and

(iii) CDR-H3, which has a sequence of CDR-H3 contained in the VH as shown by SEQ ID NO: 7, or has a sequence with one or more substitutions, deletions or additions relative to the sequence of CDR-H3 contained in the VH; and/or

following three CDRs of a light chain variable region (VL):

(iv) CDR-L1, which has a sequence of CDR-L1 contained in a VL as shown by SEQ ID NO: 8, or has a sequence with one or more substitutions, deletions or additions relative to the sequence of CDR-L1 contained in the VL;

(v) CDR-L2, which has a sequence of CDR-L2 contained in the VL as shown by SEQ ID NO: 8, or has a sequence with one or more substitutions, deletions or additions relative to the sequence of CDR-L2 contained in the VL; and

(vi) CDR-L3, which has a sequence of CDR-L3 contained in the VL as shown by SEQ ID NO: 8, or has a sequence with one or more substitutions, deletions or additions relative to the sequence of CDR-L3 contained in the VL;

wherein, the substitutions in any one of (i) to (vi) are conservative substitutions;

wherein, CDR-H1, CDR-H2 and CDR-H3 contained in the heavy chain variable region (VH), and/or CDR-L1, CDR-L2 and CDR-L3 contained in the light chain variable region (VL) are defined by a Kabat, Chothia or IMGT numbering system.